ArticleeGastroenterology2026
Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023.
Article in eGastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CHAIN Cohort: Prospective Multicenter Study of MASLD With Serial Liver Stiffness Assessments in Cardiovascular Care.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- A roadmap for heart-liver co-management in MASLD.Military Medical Research · 2026Article
- Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies.eGastroenterology · 2026Review
- Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH).Drug design, development and therapy · 2026Review
- Immunotherapy in HCC: aetiology matters.eGastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing health problem in the Asia-Pacific region, contributing significantly to morbidity and healthcare burden. This study provides a comprehensive analysis of the burden of MASLD across countries and territories in the Asia-Pacific region from 1990 to 2023. Methods: We used the Global Burden of Disease 2023 data set to assess the burden of MASLD in the Asia-Pacific region, calculating age-standardised prevalence, incidence, death and disability-adjusted life year (DALY) rates. Temporal trends, age-specific and sex-specific patterns, and the relationship between MASLD burden and Socio-demographic Index (SDI) were also analysed, along with regional variations driven by ageing, population growth and epidemiological changes. Results: In 2023, MASLD prevalence varied across the Asia-Pacific region, with the highest rates in Oceania (15 360.55 per 100 000), Central Asia (15 201.10 per 100 000), South-East Asia (15 116.91 per 100 000) and East Asia (15 042.06 per 100 000), and lower rates in Australasia (9336.02 per 100 000) and high-income regions (8654.71 per 100 000). Over the past three decades, MASLD prevalence has increased across all regions, with the largest growth in Australasia (29%) and East Asia (27%). In addition, marked regional disparities were observed in age-standardised death and DALY rates, with Central Asia exhibiting the highest health loss across the region. Age-stratified analyses revealed that the highest incidence occurred in individuals aged 20-24 years in 2023. MASLD burden followed an inverse U-shaped pattern with SDI, increasing in regions with lower SDI and decreasing in those above 0.62. Population growth and lifestyle changes were the primary drivers of MASLD in East Asia, while ageing significantly contributed to the rising burden in South Asia. Conclusions: MASLD is increasingly prevalent across the Asia-Pacific region, driven by ageing, population growth and epidemiological changes, with significant regional variations in the disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.